Cells (Oct 2024)

Decompensated MASH-Cirrhosis Model by Acute and Toxic Effects of Phenobarbital

  • Nico Kraus,
  • Frank Erhard Uschner,
  • Magnus Moeslein,
  • Robert Schierwagen,
  • Wenyi Gu,
  • Maximilian Joseph Brol,
  • Eike Fürst,
  • Inga Grünewald,
  • Sophie Lotersztajn,
  • Pierre-Emmanuel Rautou,
  • Marta Duran-Güell,
  • Roger Flores Costa,
  • Joan Clària,
  • Jonel Trebicka,
  • Sabine Klein

DOI
https://doi.org/10.3390/cells13201707
Journal volume & issue
Vol. 13, no. 20
p. 1707

Abstract

Read online

Metabolic dysfunction-associated Steatohepatitis (MASH), is a prominent cause for liver cirrhosis. MASH-cirrhosis is responsible for liver complications and there is no specific treatment. To develop new therapeutic approaches, animal models are needed. The aim of this study was to develop a fast animal model of MASH-cirrhosis in rats reflecting the human disease. Carbon tetrachloride (CCl4) injections in combination with a high-fat Western diet (WD) were used to induce MASH-cirrhosis. To accelerate liver injury, animals received phenobarbital (PB) in their drinking water using two different regimens. Rats developed advanced MASH-cirrhosis characterized by portal hypertension, blood biochemistry, hepatic ballooning, steatosis, inflammation and fibrosis. Importantly, rats receiving low-dose PB for the long term (LT) showed ascites after 6 weeks, whereas rats with high-dose short-term (ST) PB developed ascites after 8 weeks. ST- and LT-treated rats showed increased portal pressure (PP) and decreased mean arterial pressure (MAP). Of note, hepatocyte ballooning was only observed in the LT group. The LT administration of low-dose PB with CCl4 intoxication and WD represents a fast and reproducible rat model mimicking decompensated MASH-cirrhosis in humans. Thus, CCl4 + WD with LT low-dose phenobarbital treatment might be the preferred rat animal model for drug development in MASH-cirrhosis.

Keywords